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Pancreatic resectiona b s t r a c t
Radiation therapy (RT) is a valuable component of multimodal treatment for localized pancreatic cancer.
Intraoperative radiation therapy (IORT) is a very precise RT modality to intensify the irradiation effect for
cancer involving upper abdominal structures and organs, generally delivered with electrons (IOERT).
Unresectable, borderline and resectable disease categories benefit from dose-escalated chemoradiation
strategies in the context of active systemic therapy and potential radical surgery. Prolonged preoperative
treatment may act as a filter for selecting patients with occult resistant metastatic disease. Encouraging
survival rates have been documented in patients treated with preoperative chemoradiation followed by
radical surgery and IOERT (>20 months median survival, >35% survival at 3 years). Intensive preoperative
treatment, including induction chemotherapy followed by chemoradiation and an IOERT boost, appears
to prolong long-term survival within the subset of patients who remain relapse-free for>2 years
(>30 months median survival; >40% survival at 3 years). Improvement of local control through higher
RT doses has an impact on the survival of patients with a lower tendency towards disease spread.
IOERT is a well-accepted approach in the clinical scenario (maturity and reproducibility of results), and
extremely accurate in terms of dose-deposition characteristics and normal tissue sparing. The technique
can be adapted to systemic therapy and surgical progress. International guidelines (National
Comprehensive Cancer Network or NCCN guidelines) currently recommend use of IOERT in cases of close
surgical margins and residual disease. We hereby report the ESTRO/ACROP recommendations for per-
forming IOERT in borderline-resectable pancreatic cancer.
 2020 The Author(s). Published by Elsevier B.V. on behalf of European Society for Radiotherapy and
Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Pancreatic cancer is the seventh leading cause of cancer death
worldwide [1]. Although significant improvements in overall sur-
vival rates have been observed in the last three decades, overall
outcome remains poor [2]. Multimodality therapy including preop-
erative and adjuvant systemic treatment with RT components areneeded for disease that is locally advanced or borderline resectable
on presentation. Surgery is a curative element of therapy, although
few patients present with resectable disease [3,4].
For locally advanced disease including borderline imaging
resectability, preoperative treatment with systemic agents and/or
external beam radiotherapy (EBRT) (18 studies published from
1966 to 2015, 959 patients analysed) reported an objective
response in 31.5%; 65.3% underwent resection (57.4% R0) with a
median survival of 17.9 months (25.9 months for resected
patients) [5]. The potential of preoperative therapy in borderline
Table 2
Institutional contemporary experiences regarding IOERT component in borderline
resectable disease treated with preoperative chemoradiation with or without
FOLFIRINOX induction.
Parameter Mayo Clinic 2013 [16] MGH 2018 [15]
Period of analysis 2002–2010 2010–2015
Initial local status:
& Resected/Borderline 11 (35%) 8 (12%)
& Median T size – 3.6 cm
Preoperative therapy
& Chemo-radiation 31* 68*
& Induction FOLFIRINOX – 68*
Resected
& # patients 17 (55%) 41 (60%)
& R0 11 (65%) 19 (46%)
& R1 5 (29%) 16 (39%)
& R2 1 (6%) 6 (15%)
IOERT
& # patients 14 of 17 (79%) 22 of 41 (54%)
& Dose range 10–15 Gy 8–13 Gy
Outcomes for resection + IOERT
& Local control 94% 73%
& Median OS 23 months 35 months
& 3 years OS + 40% –
MGH: Massachusetts General Hospital, IOERT: IntraOperative Electron Radiation
Therapy, R0: complete resection of the tumour or complete remission, R1: micro-
scopic residual tumour, R2: macroscopic residual tumour, LC: Local control, OS:
Overall Survival, * Entire group
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operative FOLFIRINOX (5-Fluorouracil, irinotecan and oxaliplatin),
the meta-analysis data for patients with borderline pancreatic can-
cer (13 studies, 253 patients) shows a tendency towards favourable
resection rates of 39.4% and R0 specimens of 63.5% [7]. Interna-
tional pooled analysis (518 patients) has indicated that postopera-
tive RT significantly improves survival: 23.0 months with doses
of>45 Gy with conventional fractionation vs 13.0 months with
doses of less than 45 Gy with conventional fractionation [8].
Clinical results of intraoperative radiation therapy (IORT) using
high-energy electron beams (IOERT) have been consistently
reported in the last four decades [9,10]. IOERT used as a boost strat-
egy (integrated for a dose-escalation multimodality approach) or as
the only RT component was tested for localized non-resected, bor-
derline or post-resection pancreatic cancer [11,12]. Favourable
improvement in local control has been described in cohorts treated
with extended resection through the addition of intraoperative irra-
diation [13,14]. In this decade, IOERT is considered a risk-adapted
methodology for maximizing loco-regional control as a safe, accu-
rate and efficient radiation dose-escalation technique [15–17].
In this study, the ESTRO IORT Task Force working group reports
recommendations for performing in resected and in borderline
resectable pancreatic cancer underwent resection after preopera-
tive treatment (borderline-resected). These recommendations aim
to define clinical indications, patient selection and technical aspects
in a multidisciplinary setting in order to standardize treatment
modalities across centres already using IOERT, and to help institu-
tions that intend to start IOERT programmes for pancreatic cancer.2. Evidence review and update
We performed a retrospective bibliographic review of time-
period, treatment strategies, disease characteristics and clinical
results reported, including an intraoperative irradiation compo-
nent, typically with electrons (IOERT) between 1981 and 2016.
Table 1 contains data evaluated in 31 reports on post-resection dis-
ease status (1,435 patients analysed) [12,14–17,18–44].
Table 2 summarizes contemporary clinical results [15,16],
including preoperative induction chemotherapy, chemo-radiation
and surgical exploration (with or without resection, with or with-
out IOERT) in unresectable or borderline resectable disease.
In 2017, Krempien et al. published an IOERT review on pancre-
atic cancer with a selective update of post-resected status results
[11].Table 1
Chronologic data analysis from a 35 years literature review period on IORT for Pancreatic
Treatment Characteristics 1981–1989 1990–1999
Resected
& #Studies 5 12
& #Patients 46 257
References [18–21,28] [14,22–24,2
IORT
& Dose range (Gy) 10–40 10–30
& Mean dose (Gy) 25 15
& Electron beam 100% 100%
& 250 kV – –
EBRT delivered
> 50% patients 75% 39%
Adjuvant CT
> 50% pts 0% 70%
Median Survival
& Range (months) 5–12.6 10–19
& Mean (months) 9.5 15
IORT: IntraOperative Radiation Therapy; EBRT: external beam radiotherapy; CT: chemo3. Pre-treatment investigations
Studies required for candidate selection include the following:
1. Pathology of adenocarcinoma
2. History and physical examination
3. American Society of Anaesthesiologists (ASA) score
4. Conventional blood tests
5. CA 19.9
6. Abdominal Multidetector computed tomography angiography
7. Esophago-gastric duodenoscopy and Endoscopic
ultrasonography
8. Chest computed tomography (CT)
Potential supportive actions to be considered preoperatively













therapy; Gy: Gray; kV: kilovoltage
Table 3
Patient selection for IOERT: disease, treatment sequence and radiation dose
recommendations.
Disease Status
Clinical setting Borderline resected pancreatic cancer
F.A. Calvo et al. / Clinical and Translational Radiation Oncology 23 (2020) 91–99 931. Self-expanding stent
2. Gastro-jejunostomy
3. Neurolysis
Additional studies in high-risk patients, as clinically indicated,
include the following:
1. Magnetic Resonance Imaging (MRI) / magnetic resonance
cholangiopancreatography
2. Positron Emission Tomography (PET)-CT
3. Laparoscopy
4. Pre-treatment imaging for clinical staging
Accurate diagnosis, clinical staging and treatment of pancreatic
cancer require extensive interdisciplinary interaction and coopera-
tion between specialties (diagnostic radiology, interventional
upper endoscopy, nuclear medicine, surgery, medical oncology,
radiation oncology). Accurate clinical staging is based on angio-
graphic high-quality (helical) multidetector computed tomography
(CT) with advanced volumetric techniques to accurately define the
relationship of the tumour to the celiac axis and superior mesen-
teric vessels in three dimensions. In the absence of extrapancreatic
disease, the relationship of the low-density tumour mass to the
superior mesenteric artery (SMA) and celiac axis is the main focus
of preoperative imaging studies. Endoscopic ultrasound-guided
needle biopsy is a preferred method of diagnosis. Endoscopic retro-
grade cholangiopancreatography may be of use in decompression
of the biliary tract in patients with jaundice and pruritus. Local
tumour resectability is most accurately assessed by preoperative
imaging studies: intraoperative exploration is an inadequate
method to assess critical tumour–vessel relationships [45,46].
Objective, reproducible radiographic criteria define potentially
resectable disease as the absence of extrapancreatic disease,
absence of superior mesenteric vein (SMV) or portal vein encase-
ment, abutment or distortion, or associated thrombi, and presence
of a patent SMV–portal vein confluence and distinct fat planes
around the SMA, celiac axis and hepatic artery [47]. Pre-
treatment staging to exclude patients with locally advanced dis-
ease is crucial to allow for accurate interpretation of results from
studies examining the value of multimodality therapy in patients
with pancreatic cancer. Borderline resectable tumours, which
may benefit from preoperative therapy, include tumours with
abutment or encasement of the SMV/portal vein without arterial
involvement, in which sufficient vessel is present proximally and
distally to permit resection and venous reconstruction, gastroduo-
denal artery encasement without extension to the celiac axis and
with or without abutment or minor encasement of the hepatic
artery, abutment of less than 180 of the SMA [48]. The margin
most frequently reported as positive in patients who undergo pan-
creaticoduodenectomy is along the SMV or proximal SMA. IOERT
following pancreatic resection should accurately document the
pathologic status of the retroperitoneal margin of resection. PET-
CT at initial staging contributes complementary information on
potential distant metastasis and the metabolic profile of the pri-
mary lesion [49].Indications Borderline/resected
Stage > IA (UICC TNM, 2016)
Treatment
Preoperative chemoradiation followed by resection + IOERT boost
Radiotherapy Dose
IOERT boost 10 to 12.5 Gy for negative resection margins (R0)
12.5 to 15 Gy for microscopic positive resection margins
(R1)
15 to 20 Gy for macroscopic or gross residual tumor (R2)
3D-CRT or
IMRT
45–50.4 Gy (in 1.8–2 Gy per fraction)5. Patient selection for IOERT
All patients diagnosed with localized pancreatic cancer have to
be extensively evaluated and discussed at a multidisciplinary
tumour board (MTB) for defining the optimal multimodal treat-
ment strategy, including exploratory laparotomy, with or without
resection, and IOERT.A significant proportion of unresectable or borderline resectable
patients will be advised to undergo preoperative strategies (includ-
ing a preoperative chemoradiation component) and should be
restaged before laparotomy in terms of performance status, imag-
ing and CA19.9 evolution.
Patients amenable to the multidisciplinary approach including
IOERT should have a good performance status (ECOG less than 2)
and without distant metastases. The strongest recommendation
exists for patients with clinical stage > IA (UICC TNM, 2016).
Table 3 reports patient selection for IOERT: disease status, treat-
ment sequence and radiation dose recommendations.6. External beam radiation therapy
For patients with borderline-resectable cancers, pre-operative
EBRT plus concurrent chemotherapy is preferably given prior to
exploratory laparotomy and possible surgical resection/IOERT.
External-beam radiation therapy (EBRT) is delivered using 3-
dimensional conformal irradiation (3D-CRT) or intensity-
modulated irradiation (IMRT), daily, over a period of 5–6 weeks
at a dose of 45.0–50.4 Gy in 1.8 daily fractions, together with 5-
FU, capecitabine or institutional chemo-radiation regimes. IMRT
shows dosimetric advantages, sparing renal and liver parenchyma,
stomach and small bowel. The planning target volume (PTV) takes
into account organ motion and encompassing the clinical target
volume (CTV) that includes areas consisting of the tumour itself
and areas at risk of tumour involvement and occult (at-risk) nodal
metastases. Nodal target volumes for tumours in the head of the
pancreas include the pancreaticoduodenal, peripancreatic, porta
hepatis, celiac and suprapancreatic nodes. The portion of the duo-
denal loop at risk of involvement with extrapancreatic tumour
extension is also included. For lesions involving the body and tail
of the pancreas, the suprapancreatic, celiac and splenic hilar nodes
should be included in the CTV; inclusion of more medially placed
lymph nodes (pancreaticoduodenal and porta hepatis) may be
optional, depending on the ability to spare normal organs and
structures. Normal tissue tolerances should be carefully respected.
Details regarding dose-volume histogram parameters for treat-
ment of pancreatic malignancies with RT have been recently
updated (50). The dose limits of the kidneys, liver, stomach, small
bowel and spinal cord will influence the selection of beam arrange-
ment. In situations where IOERT has been administered or is
intended to be administered to tumour or tumour bed located in
proximity of vertebral column, the spinal-cord dose should be lim-
ited to 35.0–40.0 Gy. In the postoperative setting, similar planning
principles can be used, with the operative bed and areas of poten-
tial residual tumour or microscopic extension taking the place of
the initial gross tumour volume in treatment planning.
Fig. 1. A post-pancreatectomy tumour bed area including the description of
remaining anatomical structures. SMA: superior mesenteric artery.
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7.1. Surgical factors and tumour resection (pancreaticoduodenectomy;
distal pancreatectomy)
Pancreaticoduodenectomy involves the excision of the pancre-
atic head, duodenum, gallbladder and bile duct, with or without
removal of the gastric antrum. Access to the peritoneal cavity is
through a longitudinal midline incision or a bilateral subcostal
incision. Once in the abdominal cavity, all intra-abdominal organs
and peritoneal surfaces are carefully inspected and palpated to
exclude distant metastatic disease. Any suspicious lesions should
be biopsied and sent for frozen-section examination, as presence
of distant metastasis is a contraindication to proceeding with
resection. A wide Kocher manoeuvre is performed lifting all lym-
phatic tissue over the medial aspect of the right kidney, inferior
vena cava and left renal vein. The gastrocolic ligament is divided,
with special attention to preserving the gastroepiploic arcade if
pyloric preservation is being entertained. The neck of the pancreas
is then carefully dissected off the SMV. Dissection of the porta hep-
atis is usually initiated by excising the common hepatic artery
lymph node to facilitate exposure. The gastroduodenal and right
gastric artery are identified, legated and divided. The superior por-
tion of the pancreatic neck is dissected off the portal vein. Chole-
cystectomy is then performed and the common hepatic duct is
divided. The gastric antrum or duodenum is divided using a liner
gastrointestinal stapler. The jejunum is then transected approxi-
mately 10 cm from the ligament of Treitz with subsequent mobi-
lization of its mesentery, as well as mobilization of the third and
fourth portions of the duodenum. The pancreatic neck is tran-
sected. The pancreatic head and uncinate process are now dis-
sected from the portal vein and SMV by legating and dividing the
often-multiple venous tributaries that are encountered. Vascular
resection of the SMV–portal vein confluence using either lateral
venectomy or segmental venous resection and reconstruction
should be performed when there is no tissue plane between the
tumour and SMV and portal vein. Medial retraction of the SMV–
portal vein confluence and the SMA is identified. All of the soft tis-
sue along the right lateral aspect of the SMA should be excised.
Special attention should be paid to this step, given the high inci-
dence of local recurrence. In spite of all efforts, a microscopically
positive margin will occur in between 10% and 20% of cases due
to perineural invasion along the mesenteric plexus at the SMA ori-
gin and microscopic lymphatic spread beyond the extent of the
palpable tumour. Prior to obtaining frozen-section histologic
examination of the surgical margins, the specimen is appropriately
oriented and the areas in question are identified. Reconstruction
after pancreaticoduodenectomy have to be start after IOERT proce-
dure to avoid irradiation of anastomotic structures (see below).
Reconstruction will be start with the pancreaticojejunostomy. A
retrocolic end-to-side duct-to-mucosa technique using interrupted
sutures is recommended. Then, distal to the pancreaticojejunos-
tomy, the hepaticojejunostomy is completed in a single layer using
either interrupted or running sutures, depending on the calibre of
the common hepatic duct. An antecolic, end-to-side duodenoje-
junostomy (or gastrojejunostomy if pyloric preservation has not
been used) in two layers is then completed approximately 40–
50 cm from the hepaticojejunostomy. The abdomen is then irri-
gated copiously prior to placing surgical drains and performing
abdominal closure. Perhaps one of the most debated technical
aspects of the pancreaticoduodenectomy is the extent of the asso-
ciated lymphadenectomy (standard vs extended). A standard lym-
phadenectomy (standard pancreaticoduodenectomy) commonly
refers to the resection of gastric and pyloric nodes, nodes to the
right of the hepatoduodenal ligament, anterior and posterior pan-
creaticoduodenal nodes, nodes to the right of the SMA and nodesanterior to the common hepatic artery. An extended lymphadenec-
tomy (extended pancreaticoduodenectomy) includes the skele-
tonization of the common and proper hepatic arteries, celiac axis
nodes, all nodes to the left and right of the hepatoduodenal liga-
ment, circumferential skeletonization of the SMA between the
aorta and the inferior pancreaticoduodenal artery, all nodes in
the anterolateral aspect of the aorta and the inferior vena cava,
in continuity with Gerota’s fascia, between the celiac axis and
the inferior mesenteric artery.
8. IOERT procedure: Post-resection
8.1. IOERT: Methods and techniques of treatment
IOERT for pancreatic cancer has predominantly been delivered
with megavoltage electrons (IOERT) produced by a medical linear
accelerator (Fig. 1) [50]. Although brachytherapy and orthovoltage
treatment have been described, the data on efficacy is uncertain.
Therefore, these recommendations will focus IOERT. The electron
beam energy and dose of IOERT are determined by the resection
status and geometry of the treated field. Bolus is not recommended
due to the fact that intraoperative fluid is present after tissue
manipulation and resection. Protections inside the tumour bed
are not recommended too, due to the dosimetric uncertainties
introduced by such action. The best protection is mechanical
retraction for temporary displacement of dose-sensitive structures
at risk. Surgical retractors for large upper abdominal interventions
are most helpful for properly exposing the radiation target and for
expediting IOERT applicator positioning, displacement of normal
tissue and iconographic documentation of the final pre- and
post-intraoperative irradiation assemblage.
9. Radiation target definition
After marginal resection of borderline resectable or resectable
lesions, the tumour bed contains retroperitoneal soft tissue, vascu-
lar structures (portal vein, superior mesenteric artery and vein,
aorta), the prevertebral ligament and the anterior part of the verte-
bral bone (Fig. 1).
The sectioned bile duct, the pancreatic remnant, colon and
stomach are excluded from the IOERT field and should be under
visual control and mechanically retracted. The upper pole of the
right kidney can also be controlled and displaced by palpation.
Under appropriate haemostasis, intraoperative fluid is not a limit-
ing factor for selection of electron beam energy as long as the fluid
level covering the target volume is stable. The target at risk should
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tures and the post-resected retroperitoneal surface with a safety
margin, which can be adequately treated with lower-energy elec-
trons in the 9–12 MeV range. Intraoperatively, the radiation oncol-
ogist and surgeon consult regarding the retroperitoneal area at risk
of residual tumour after maximal resection, and the volume at risk
is encompassed within a field defined by an IOERT applicator with
a margin of at least 1–2 cm laterally, covering the PTV including
anatomic, dosimetric and geometric uncertainties; in depth, a mar-
gin of 0,1–0,5cm margin should allow for penetration uncertain-
ties. The post-pancreatectomy tumour bed is appropriately
encompassed by applicators in the range of 7 to 10 cm. For larger
field sizes, consider the use of bevelled applicators; field abut-
ments should be discouraged. Fig. 2 illustrates an IOERT applicator
in position for treatment of a tumour bed post-pancreatectomy.
The whole process can be summarized as follows:
1. Tumour bed definition/assessment: surgical margin status
(inspection of the surgical field and the posterior aspect of the
surgical specimen; optional frozen section pathology). Perivas-
cular tissue characteristics in borderline lesions.
2. Normal uninvolved tissue to be excluded (mobilized out) from
the IOERT radiation volume: bile duct (sections); pancreatic
remnant (sectioned if it exists); stomach; colon; small bowel;
liver; upper pole of right kidney.
3. Normal tissue at risk to be included in the radiation target vol-
ume: circumferential vasculature structures (inferior cava vein;
portal vein; superior mesenteric artery and vein, aorta; legated
left gastric artery); lymphatic and retroperitoneal soft tissue;
prevertebral ligament.
Such decisions should be agreed at the time of IOERT.10. Applicator selection
The applicator selection and adaptation to the post-surgical bed
at risk should consider the following technical elements of
decisions:Fig. 2. IOERT applicator positioned encompassing the tumour bed (vascular
structures and retroperitoneal tissue margin) excluding from the radiation beam:
pancreatic stump, bile duct, liver and transverse colon. SMA: superior mesenteric
artery.1. Size (diameter): in the range of 1 to 2 cm larger than the orig-
inal maximal dimension of the tumour (T) in the staging imag-
ing studies, including the area at risk or positive margins.
Availability of applicators with a diameter of 5 to 10 cm pro-
vides a safe range.
2. Bevel angle: to appropriately encompass the surgical bed the
anatomical configuration of the right sided head of the pancreas
surgical bed, 15 to 30 bevel angles are recommended. The
same criteria apply to primaries in the tail of the pancreas (op-
posite direction). Dominant lesions in the body of the pancreas
are properly encompassed with 0 to 15 angles.
11. IOERT irradiation
IOERT irradiation consists of the following:
1. Electron energy selection: 90% isodose should encompass in
depth the full circumference of vessels involved, in contact or
at risk, together with retroperitoneal tissue and prevertebral
ligament. The estimations of this distance can be made using
real-time intraoperative measurements, together with data
obtained from the presurgical CT scan. Meticulous haemostasis
and intra-abdominal surgical fluid are relevant for electron
energy selection. In the event of fluid instability at the radiation
target, a superior electron energy level selection is an
alternative.
2. Dose selection (single fraction boost component): resection
specimens at low risk after favourable dissection procedure
doses of 10 to 12.5 Gy are recommended. Specimen with close
or suspected/confirmed cancer involved margins doses in the
range from 12.5 to 15 Gy are recommended. After laborious
vascular and/or soft tissue dissection with suspected residual
cancer, 15 to 20 Gy should be considered, even in the event of
vascular anastomosis.
12. Dose prescription
For tumours resected without identifiable residual gross
tumour volume, doses in the range of 10.0–12.5 Gy are applied.
Depending on the extent of suspected residual microscopic malig-
nant disease, this range may be 12.5–15 Gy. For gross residual dis-
ease, doses of 15–20 Gy have been employed. During surgery, care
must be taken to accurately identify the depth of the spinal cord
beneath the IOERT field using anatomic landmarks and a review
of preoperative CT imaging. A library of predefined isodose curve
distribution for a range of IOERT applicator diameters, bevel shapes
and electron beam energies has to be available for intraoperative
consultation (Fig. 3). The electron energy should be chosen to ade-
quately encompass the target tissues within the 90% isodose
curves, with attention to the spinal cord dose contribution.13. Treatment delivery
Before dose delivery, the appropriate physical and dosimetrical
parameters (electron energy, applicator size, length and bevel
angle, monitor units, bolus choice, should be checked by a medical
physicist as well as by the physician (radiation oncologist) in a
four-eyes principle. Usually, a medical physicist or a radiation ther-
apist (RTT) aligns the gantry to the applicator for soft-docking sys-
tem and enters the data in the control console. During irradiation
(approximately 1–2 min, depending on dose and dose rate),
nobody is allowed to stay in the operation room except the patient
for radiation protection purposes.
Fig. 3. A virtual 2D simulation (7 cm diameter applicator, 15 bevel angle) and dosimetric representation (10 MeV electron beam) of an IOERT post-pancreatectomy
procedure: A. CT contoured including tumour, adjacent organs at risk and upper abdominal vasculature, B. Post resected tumour bed estimation (3D): retroperitoneal tissue
and vasculature, C. Applicator positioning: 7 cm diameter, 15  bevel angle and D. Isodose distribution: 10 MeV electron beam.
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After IOERT irradiation, the surgeon or radiation oncologist per-
forms applicator removal with the assistance of a surgical assis-
tant/nurse.
Special attention should be paid during this step to avoid
traumatization of surrounding tissues and possible bleeding. In
the event of bleeding during irradiation, blood should first be aspi-
rated in order to clearly visualize the end of the collimator in con-
tact with the patient’s tissues and allow for a safe manoeuvre.
15. Recording and reporting
Clinical and dosimetry forms should be filled out with all rele-
vant patient, tumour and treatment parameters. Clinical data
should include demographic data, performance status, symptoms
and serum tests, including CA19-9, comorbidities and Charlson
comorbidity index. Tumour-related data should include imaging
studies, a biopsy report, clinical and pathological stage, grading
and possible biomolecular studies. Treatment data should include
bile-duct permeability manoeuvres, preoperative treatments, the
surgical report and main characteristics of the IOERT procedure,
including applicator diameter, bevel angle, bolus, beam energy,
dose prescription and duration of the procedure. In vivo dosimetry
is strongly recommended as a quality-assurance procedure. Radia-
tion target contents should be described: organs and structures
included in the radiation beam. Radiation protection of normal
uninvolved tissues: description of temporary mobilization or
intra-field customized protection. The documentation of the radia-
tion target, adjacent - if necessary mobilized - normal tissue and
used shielding should ideally include drawings or photos.
Preoperative MRI and CT-scans can be obtained to identify the
primary tumour, regional lymph nodes and critical organs in order
to design a provisional treatment plan. No fully reliable treatment
planning systems currently exist for intraoperative irradiation;
however, the availability of preoperative images may help withidentifying anatomical structures to guide the positioning of the
collimator. Whenever obtained, all these imaging data should be
included in the patient’s final documentation. Additionally, clinical
photographs of the applicator positioning and surface anatomy in
the IOERT target volume are recommended.
Intraoperative ultrasound can also be helpful in some cases to
verify tumour size in depth and the location of critical structures
such as kidneys and major vessels.
The final documentation of the IOERT procedure should also
include the surgical notes and the anaesthesiology report.
Table 4 contains a summary of the relevant IOERT parameters
for local treatment.16. Recommendation on patient care:
16.1. Care during the course of IOERT
The sterile field should be guaranteed throughout the IOERT
procedure. Before irradiation, sterile drapes should cover the surgi-
cal bed and the part of the applicator inside and near the surgical
bed. In some cases, an aspiration drain may be useful to avoid
bleeding outside the surgical bed. The patient should be carefully
observed by means of a camera during irradiation and vital param-
eters should be monitored and be visible from outside the operat-
ing room. In the event of an emergency, irradiation should be
stopped immediately and nurses, anaesthesiologists and surgeons
should be prepared to enter the operating room at any time imme-
diately after cessation of irradiation.17. Post-treatment patient care and follow-up
Patients treated with IOERT for pancreatic tumours require
thorough care, as after any other surgical procedure for pancreatic
tumours. All vital and clinical parameters should be monitored in
the days following the procedure, and special attention should be
Table 4
Reporting parameters for IORT electrons beam procedures in resected pancreatic
cancer.
Iort Parameters
Target volume description - Tumour residue (R0, R1, R2)
- Normal tissues exposed




IORT factors - Applicator size/diameter




- Number of fields






- Time of beam on
- Gantry angulation




- Surgery: type of resection and margin
status (R0, R1, R2)
& Technique and reconstruction
- Preoperative
& Chemoradiation (CRT)
& Induction chemotherapy + CRT
- Postoperative
& CRT
& CRT + adjuvant chemotherapy
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movements and onset of new symptoms and signs.
After IOERT for pancreatic-head tumours, the risk of duodenal
radiation damage, even with bleeding, should be taken into
account. In the event of persistent pain and anaemia with faecal
occult blood, medical therapy and endoscopy/surgical procedures
should be considered.
In the case of unresected or partially resected lesions, the risk of
bleeding related to haemorrhage from arteries and veins encased
by the tumour tissue that undergoes necrosis should be carefully
considered. In the event of significant bleeding, re-operation aim-
ing at haemostasis should be considered where possible.
After the IOERT procedure, alone or combined with surgical
resection, the patient may receive further treatments, including
postoperative RT and adjuvant systemic treatment. Therefore, the
follow-up schedule starts after treatment completion and usually
does not substantially differ from that of pancreatic cancer treated
without IOERT. During imaging studies, special attention should be
paid to any tissue potentially involved in the IOERT volume such as
the duodenum and major vessels.18. Adverse effects
IOERT in the setting of post-resection pancreatic cancer is typi-
cally well tolerated. In the European pooled analysis, acute treat-
ment toxicity was minimal and limited to grade 2. Surgical
adverse events consisted of pancreatic fistula in 27%, delayed gas-
tric emptying in 22%, haemorrhage in 18%, repeat laparotomy in
15%, abdominal abscess in 14%, sepsis in 3%, and perioperative
mortality in 2% [42]. Large animal experimental studies have anal-
ysed the pathologic response of the pancreas and duodenum [51].
Clinical and experimental data of upper abdominal tissues and
organs support good tolerance to a 10-Gy to 20-Gy IOERT boostplus 50-Gy external beam RT (conventional fractionation), includ-
ing post-resection vascular anastomosis [52,53].19. Conclusions and future directions
Long-term survival and disease control are achievable in
selected patients with borderline-resectable pancreas cancer, with
a tendency towards improved survival reported for patients who
underwent resection after intensive-induction systemic and
locoregional full-dose chemoradiation. IOERT as part of a multi-
modality treatment option for borderline or resected pancreatic
cancer has been shown to promote high local control at the site
of the primary tumour without a significant increase in treatment
toxicity. With advances in the ability of systemic therapy to treat
occult systemic metastases, the importance of sustained long-
term local and regional control is increasing interest in the expan-
sion of IOERT.
Strategies for selecting appropriate patients for aggressive local
therapy in resected and borderline-resectable settings will advance
through improvements in imaging, biomarkers and genetics, as
well as through the timing of when to administer IOERT and/or
resection. In-vivo-dosimetry and intra-operative imaging should
be encouraged to improve the accuracy, reproducibility and docu-
mentation and provide data for evaluation and tailoring of IOERT.
IOERT is a risk-adaptable technique in the era of personalized
oncology [54]. New opportunities for systemic or regional therapy
(intrahepatic and intraperitoneal), targeted therapies, vaccines and
immunotherapy should be evaluated in an attempt to improve sys-
temic disease control. As improvements are being made in distant
disease control, the benefit of improved local control with regi-
mens including IOERT may become even more decisive [55,56].20. Disclosures
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